Abstracts

GROWING UP WITH HIV

The World Health Organization estimates that over 4 million children have been infected with HIV, most via vertical transmission. Before effective treatment, mortality rates of 50% within the first two years of life were expected. The availability of safe and effective ART has radically changed this outcome and most children living with HIV infection who…

INTEGRATING NEW ANTIRETROVIRAL THERAPIES

The ‘pipeline’ of candidate anti-HIV drugs includes novel classes, novel mechanisms of action, biologics and broadly neutralizing monoclonal antibodies. Formulations under development include a diverse range of options such as long-acting oral weekly products and implants capable of providing treatment for several months. Patient acceptability survey outcomes of LA/ER injectable Cabotegravir-Rilpivirine in phase III trials…

BROADLY NEUTRALIZING ANTIBODIES FOR HIV PREVENTION AND TREATMENT:DREAM OR PIPE DREAM?

Small molecule inhibitors of HIV-1 replication have transformed antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP). Despite these successes, for many persons living with or at risk of acquiring HIV infection, the burden of taking daily medication poses significant challenges. Monoclonal antibodies that neutralize a broad range of HIV-1 isolates (bNAbs) may provide a long-acting alternative…

TRANSITIONING TO NEW GENERIC ANTIRETROVIRALS IN SUB-SAHARAN AFRICA

The pricing of drugs has influenced national ARV treatment guidelines in many Sub Saharan countries. The new possibility of integrase inhibitors – mostly dolutegravir (DTG) as first line was becoming a reality. This development called for policy adoption and introduction into national treatment guidelines, planning for roll-out, streamlining, and strengthening supply chain systems; all in…

GLOBAL ELIMINATION OF HEPATITIS C

With the remarkable advances in therapy for hepatitis C virus (HCV) infection, almost all infected individuals can now be cured with short-course, well-tolerated therapy. The success of current treatment has raised the prospect that perhaps this chronic infection could actually be eliminated as a public health threat on a global scale. With this in mind,…

THE RISING CHALLENGE OF LIVER CANCER

In 2015 there have been 854,000 incident cases of liver cancer and 810,000 related deaths globally contributing to > 20 million disability-adjusted life-years (DALYs).Incident liver cancer increased by 75% between 1990-2015 : 47% explained by changing population age structures, 35% by population growth and 8% to changing age-specific incidence rates. Infection with the hepatitis B…